- Companies
- Genesis Molecular AI
Genesis Molecular AI Valuation, Funding & Investors
Genesis Molecular AI is valued at $430M as of August 2023.
Last Genesis Molecular AI valuation
$430M
Series B · Aug 2023
Last Genesis Molecular AI funding round
$40M
Strategic investment · May 2026
Cumulative funding Genesis Molecular AI raised
$296M
across 4 funding rounds
Key investors in Genesis Molecular AI
Andreessen Horowitz
Rock Springs Capital
Felicis
Menlo Ventures
Fidelity
BlackRock
About Genesis Molecular AI
Genesis Therapeutics is a South San Francisco-based biotechnology company applying generative AI and biophysical simulations for small-molecule drug discovery. Its Genesis Molecular AI platform designs novel therapeutics for oncology and neuroscience targets, integrating deep learning with physics-based modeling on scalable compute clusters. Founded in 2019, the firm collaborates with Roche and secures partnerships with NVIDIA for GPU acceleration, advancing pipelines for protein degraders and undisclosed modalities.
Founded
2019
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$430M (Aug 2023)
Genesis Molecular AI Valuation
Genesis Molecular AI is currently valued at $430M, based on its Series B in August 2023.
The $200M round was led by Andreessen Horowitz, with participation from Menlo Ventures, Fidelity, NVentures, Green D Ventures, T. Rowe Price and 3 other investors.
Genesis Molecular AI valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Aug 2023 | Series B | $430M |
Genesis Molecular AI Funding History
Genesis Molecular AI has raised a total of $296M across 4 funding rounds.
Genesis Molecular AI's first fundraising round was a $4M seed round in November 2019. The most recent completed round was a $40M strategic investment round in May 2026.
Genesis Molecular AI funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| May 2026 | Strategic investment | Incyte (lead) | $40M | - | Incyte expanded its collaboration with Genesis Molecular AI on May 20, 2026, providing $120 million of upfront consideration structured as $80 million in cash and a $40 million equity purchase in Genesis, along with recurring research funding, milestone payments of up to $232 million per program, potential royalties, and more than $1 billion across the five initial targets if all milestones are achieved. The strategic rationale is to broaden the AI-enabled small-molecule discovery partnership beyond the original two-target collaboration signed in February 2025, add at least five new Incyte-selected targets, and use Incyte’s proprietary experimental data to train Genesis’ GEMS platform. The earlier agreement covered two initial targets with an option for a third, a $30 million upfront payment, and up to $295 million in milestones per target. Genesis Molecular AI is an AI drug-discovery company focused on small-molecule design and platform-driven discovery. As of May 2026, the company reported having raised $200 million in funding, and its publicly described partnerships include collaborations with Incyte and Gilead. The company’s 2026 update indicates the expanded Incyte relationship is intended to accelerate model training and advance both partnered programs and Genesis’ broader platform. |
| Aug 2023 | Series B | Andreessen Horowitz (lead); Menlo Ventures; Fidelity; NVentures; Green D Ventures; T. Rowe Price; Radical Ventures; BlackRock; Rock Springs Capital | $200M | $430M | Genesis Therapeutics, also referenced as Genesis Molecular AI in some sources, is a Burlingame, California-based AI drug discovery startup developing the GEMS platform, which integrates generative and predictive AI, deep learning, molecular simulations, and chemically aware language models to design novel small-molecule therapeutics for challenging, data-poor, and previously undruggable targets. The platform accelerates hit identification through lead optimization by generating promising molecules for synthesis and testing, enabling an internal pipeline focused on oncology and other underserved areas, with partnerships including Eli Lilly (2022, up to $690M including $20M upfront) and Genentech (2020). On August 21, 2023, Genesis closed an oversubscribed $200 million Series B funding round co-led by Andreessen Horowitz's Bio + Health fund and an unnamed U.S. life-sciences investor, with participation from investors including BlackRock, Fidelity, Green D Ventures, Menlo Ventures, NVentures (Nvidia's venture arm), Radical Ventures, Rock Springs Capital, and T. Rowe Price, bringing total funding to over $280 million. An initial filing reported $224 million raised. The round valued Genesis at a $430.19 million post-money Series B valuation. Proceeds will advance the company's wholly owned AI-enabled pipeline into clinical development, expand the pipeline for new programs, and further develop the GEMS platform. Genesis plans to transition to clinical-stage with first AI-enabled drug candidates entering the clinic, positioning it among AI drug discovery players like Recursion Pharmaceuticals and Exscientia amid industry investment and skepticism. |
| Dec 2020 | Series A | Rock Springs Capital (lead) | $52M | - | The company uses its proprietary GEMS platform, combining deep learning, molecular simulations, and generative AI to discover small-molecule drugs for difficult targets, particularly in oncology and undruggable proteins. Genesis Therapeutics competed in TechCrunch Disrupt's Startup Battlefield prior to the round and has partnerships with Genentech (2020), Eli Lilly (2022, up to $690M), and Incyte (2024, up to $885M). Subsequent funding includes a $200M Series B in 2023 co-led by Andreessen Horowitz, bringing total capital raised over $280M, with investors like T. Rowe Price, Radical Ventures, Menlo Ventures, Fidelity, BlackRock, and Nvidia Ventures. The Series B funds clinical advancement, AI platform expansion, and pipeline growth across therapeutic areas. |
| Nov 2019 | Seed | Andreessen Horowitz (lead); Felicis | $4M | - | - |
Who has invested in Genesis Molecular AI?
11 investors have backed Genesis Molecular AI across its funding rounds, including Andreessen Horowitz, Rock Springs Capital, Felicis, Menlo Ventures, Fidelity and BlackRock.
Lead investors include Incyte, Andreessen Horowitz and Rock Springs Capital.
Genesis Molecular AI Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Nov 2019 | ||
| 2 | Lead | Dec 2020 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Lead | May 2026 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | Nov 2019 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | Aug 2023 | ||
This data is available for Pro users. Sign up to see all 11 Genesis Molecular AI investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialGenesis Molecular AI Competitors
Genesis Molecular AI competitors include listed companies like Fractal Analytics and Winner Technology, and private ones like Gradium, Krea, Replicant and Sarborg.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $400M | - | ||
| Private | $8M | - | $500M | 62.5x | ||
| Private | - | - | $550M | - | ||
| Private | - | - | $575M | - | ||
| Publicly listed | $344M | $50M | $1.3B | 3.4x | ||
| Publicly listed | $46M | ($7M) | $417M | - |
Genesis Molecular AI Public Comps
Genesis Molecular AI is still privately-owned, but its public comps include Winner Technology, Yidu Tech, Ropeok Technology Group, DSC Holdings, Cerence, Beijing Hanyi Innovation, Datasection, ZipRecruiter, Vrain Solution and ExaWizards.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $46M | ($7M) | 9.0x | - | (60.9x) | - | |||
| $122M | ($4M) | 1.4x | 1.2x | (45.0x) | 7.7x | |||
| $23M | ($28M) | 18.6x | - | (15.2x) | - | |||
| $101M | ($10M) | 3.3x | - | (34.3x) | - | |||
| $252M | $8M | 1.7x | 1.4x | 52.9x | 6.2x | |||
| $28M | $5M | 15.6x | 13.9x | 89.9x | 50.9x | |||
| $216M | $27M | 1.6x | 1.6x | 12.7x | 13.0x | |||
| $449M | ($7M) | 0.9x | 0.9x | (62.1x) | 7.3x | |||
This data is available for Pro users. Sign up to see all Genesis Molecular AI competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Genesis Molecular AI
| When was Genesis Molecular AI founded? | Genesis Molecular AI was founded in 2019. |
| Where is Genesis Molecular AI headquartered? | Genesis Molecular AI is headquartered in San Francisco, CA, United States. |
| Is Genesis Molecular AI publicly listed? | No, Genesis Molecular AI is a private, VC-backed company. |
| What is Genesis Molecular AI's valuation? | Genesis Molecular AI was last valued at $430M in its Series B in August 2023. |
| How much funding has Genesis Molecular AI raised? | Genesis Molecular AI has raised $296M across 4 funding rounds. |
| What was Genesis Molecular AI's last funding round? | Genesis Molecular AI's last funding round was a $40M strategic investment round in May 2026, led by Incyte. |
| Who are Genesis Molecular AI's investors? | Genesis Molecular AI's investors include Andreessen Horowitz, Rock Springs Capital, Menlo Ventures, Fidelity, Incyte, NVentures, Felicis, Green D Ventures, T. Rowe Price, Radical Ventures and 1 other. |
| Which companies are comparable to Genesis Molecular AI? | Companies comparable to Genesis Molecular AI include Gradium, Krea, Replicant, Sarborg, Fractal Analytics and Winner Technology. |
See companies similar to Genesis Molecular AI
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




